Brandes et al. Long-term Safety of Lasmiditan for Migraine – Inclusion and Exclusion Criteria

SAMURAI

Inclusion criteria:

1. Able and willing to give written informed consent and authorize Health Insurance Portability and Accountability Act (HIPAA).
2. Patients with migraine with or without aura fulfilling the International Headache Society (IHS) diagnostic criteria 1.1 and 1.2.1 (International Classification of Headache Disorders [ICHD]-2004).
3. History of disabling migraine for at least 1 year.
4. Migraine Disability Assessment (MIDAS) score ≥11.
5. Migraine onset before the age of 50 years.
6. History of 3 to 8 migraine attacks per month (<15 headache days per month).
7. Male or female, aged 18 years or above.
8. Females of childbearing potential must be using or willing to use a highly effective form of contraception (e.g., combined oral contraceptive, intrauterine device [IUD], abstinence, or vasectomized partner).
9. Able and willing to complete an electronic diary (e-diary) to record details of the migraine attack treated with study drug.

Exclusion criteria:

1. Any medical condition or clinical laboratory test that in the judgment of the investigator makes the subject unsuitable for the study.
2. Pregnant or breastfeeding women.
3. Women of childbearing potential not using or not willing to use highly effective contraception.
4. Known hypersensitivity to lasmiditan or to any excipient of lasmiditan oral tablets or any sensitivity to a ditan.
5. Known coronary artery disease, clinically significant arrhythmia, or uncontrolled hypertension.
6. History or evidence of hemorrhagic stroke, epilepsy, or any other condition placing the subject at increased risk of seizures.
7. History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo, Meniere's disease, vestibular migraine, and other vestibular disorders.
8. History of diabetes mellitus with complications (diabetic retinopathy, nephropathy, or neuropathy).
9. History within the previous 3 years or current evidence of abuse of any drug, prescription or illicit, or alcohol.
10. History of orthostatic hypotension with syncope.
11. Significant renal or hepatic impairment.
12. Subject is at imminent risk of suicide (positive response to question 4 or 5 on the Columbia Suicide Severity Rating Scale [C-SSRS]) or had a suicide attempt within 6 months prior to the Screening visit.
13. Previous participation in this clinical trial.
14. Participation in any clinical trial of an experimental drug or device in the previous 30

days.
15. Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.
16. History, within the past 12 months, of chronic migraine or other forms of primary or secondary chronic headache disorder (e.g., hemicranias continua and medication overuse headache) where headache frequency is greater than 15 headache days per month.
17. Use of more than 3 doses per month of either opiates or barbiturates.
18. Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes within 3 months prior to Screening/Visit 1.
19. Subjects who are employees of the sponsor.
20. Relatives of, or staff directly reporting to, the investigator.

SPARTAN

Inclusion criteria:

1. Able and willing to give written informed consent and authorize HIPAA.
2. Subjects with migraine with or without aura, fulfilling the IHS diagnostic criteria 1.1 and 1.2.1 (ICHD-2004).
3. History of disabling migraine for at least 1 year.
4. MIDAS score ≥11.
5. Migraine onset before the age of 50 years.
6. History of 3 to 8 migraine attacks per month (<15 headache days per month).
7. Male or female, aged 18 years or above.
8. Females of childbearing potential must have been using or willing to use a highly effective form of contraception (e.g., combined oral contraceptive, IUD, abstinence, or vasectomized partner).
9. Able and willing to complete an e-diary to record details of the migraine attack treated with study drug.

Exclusion criteria:

1. Any medical condition or clinical laboratory test which in the judgment of the investigator made the subject unsuitable for the study.
2. Pregnant or breastfeeding women.
3. Women of childbearing potential not using or not willing to use highly effective contraception.
4. Known hypersensitivity to lasmiditan or to any excipient of lasmiditan oral tablets or a sensitivity to a ditan.
5. History or evidence of hemorrhagic stroke, epilepsy, or any other condition placing the subject at increased risk of seizures.
6. History of recurrent dizziness and/or vertigo including benign paroxysmal positional vertigo, Meniere's disease, vestibular migraine, and other vestibular disorders.
7. History of diabetes mellitus with complications (diabetic retinopathy, nephropathy, or neuropathy).
8. History within the previous 3 years or current evidence of abuse of any drug, prescription or illicit, or alcohol.
9. History of orthostatic hypotension with syncope.
10. Significant renal or hepatic impairment.
11. Subject was at imminent risk of suicide (positive response to question 4 or 5 on the

C-SSRS) or had a suicide attempt within 6 months prior to the Screening visit.
12. Previous participation in this clinical trial.
13. Participation in any clinical trial of an experimental drug or device in the previous 30 days.
14. Known hepatitis B, hepatitis C, or HIV infection.
15. History, within the past 12 months, of chronic migraine or other forms of primary or secondary chronic headache disorder (e.g., hemicranias continua or medication overuse headache) where headache frequency was greater than 15 headache days per month.

GLADIATOR

Inclusion criteria:

1. Able and willing to give written informed consent and authorize HIPAA.
2. Completed SAMURAI or SPARTAN within the last 12 weeks. Patients that completed SAMURAI prior to GLADIATOR being available were allowed to enroll, as long as enrollment occurred within 4 weeks of GLADIATOR activation at their site. Patients discontinued due to administrative hold were allowed to re-enroll in the study.
3. Females of childbearing potential must have been using or willing to use a highly effective form of contraception (e.g., combined oral contraceptive, IUD, abstinence, or vasectomized partner).
4. Able and willing to complete an e-diary to record details of all migraine attacks treated with study drug.

Exclusion criteria:

1. Any medical condition or clinical laboratory test that in the judgment of the investigator made the patient unsuitable for the study.
2. Pregnant or breastfeeding women.
3. Women of childbearing potential not using or not willing to use highly effective contraception.
4. Patient was at imminent risk of suicide (positive response to questions 4 or 5 on the C-SSRS).
5. Initiation of or a change in concomitant medication to reduce the frequency of migraine episodes since completing SAMURAI or SPARTAN.
6. Participating in any clinical trial of an experimental drug or device since completing End of Study/Visit 2 of SAMURAI or SPARTAN.
7. Patient did not dose a migraine during the allotted time while enrolled in SAMURAI or SPARTAN or was evaluated to be noncompliant with the e-diary requirements (particularly recording their migraine and post-dose assessments).